39123-20-1

Basic information

• Product Name: 1-(2-Chloroethyl)-4-Methylpiperazine
• Synonyms: 1-(4-Methyl-1-piperazinyl)-2-chloroethane;2-(4-methylpiperazinyl)benzoic acid
• CAS NO: 39123-20-1
• Molecular Formula: C₇H₁₅ClN₂
• Molecular Weight: 162.6604
• Mol File: 39123-20-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(2-Chloroethyl)-4-Methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Chloroethyl)-4-Methylpiperazine(39123-20-1)
• EPA Substance Registry System: 1-(2-Chloroethyl)-4-Methylpiperazine(39123-20-1)

Safety Data

• Hazardous Substances Data: 39123-20-1(Hazardous Substances Data)

Usage

General Description

1-(2-Chloroethyl)-4-Methylpiperazine is a chemical compound with the molecular formula C7H15ClN2. It is a piperazine derivative that contains a chloroethyl group and a methyl group. 1-(2-Chloroethyl)-4-Methylpiperazine is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It is also used as a precursor in the production of certain pesticides. 1-(2-Chloroethyl)-4-Methylpiperazine may have potential applications in the field of medicinal chemistry and drug development due to its unique chemical structure and reactivity. However, it is important to handle this chemical with care, as it may pose health risks if not used properly.

Upstream product

• 5464-12-0 2-(4-methylpiperazinyl)ethanol 
• 109-01-3 1-methyl-piperazine 
• 107-04-0 1-Bromo-2-chloroethane 
• 107-20-0 2-chloroethanal 
• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 1932-03-2 2-(piperidin-4-yl)ethyl chloride 
• 5753-26-4 1-chloro-2-(4-methyl-1-piperazinyl)ethane dihydrochloride 
• 540-51-2 2-bromoethanol 

Downstream Products

• 60706-43-6 10-[2-(4-methyl-piperazin-1-yl)-ethyl]-10H-phenothiazine 
• 102598-28-7 4-(4-methylpiperazin-1-yl)-2,2-diphenylbutanenitrile 
• 138483-84-8 N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-hydroxy-6-phenyl-2(R)-<<4-<2-(4-methylpiperazin-1-yl)ethoxy>phenyl>methyl>hexanamide 
• 141308-25-0 8-methyl-7-<2-(4-methyl-1-piperazinyl)ethoxy>-2-(4-morpholinyl)-4H-1-benzopyran-4-one 
• 40172-12-1 N-ethyl-2-(4-methylpiperazin-1-yl)ethanamine 
• 100875-69-2 4-[2-(4-methylpiperazin-1-yl)ethoxy]-benzaldehyde 
• 103504-90-1 6-(4-methyl-piperazino)-4,4-diphenyl-hexan-3-one 
• 856842-64-3 6-(4-methyl-piperazino)-4,4-diphenyl-hexan-3-one-imine 
• 103157-10-4 1-[2-(4-fluoren-9-ylidenemethyl-phenoxy)-ethyl]-4-methyl-piperazine 
• 1018685-52-3 1,4-bis{3,4-bis[2-(1-methyl-piperazin-4-yl)-ethoxy]phenyl}-butane 

Relevant articles and documents

In silico/in vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives

Prion diseases or transmissible spongiform encephalopathies (TSEs) are a group of rare neurodegenerative disorders. TSEs are characterized by the accumulation of prions (PrPSc) that represent pathological isoforms of the physiological cellular prion protein PrPC. Although the conversion of PrPC to PrPSc is still not completely understood, blocking this process may lead to develop new therapies. Here, we have generated a pharmacophore model, based on anti-prion molecules reported in literature to be effective in phenotypic assay. The model was used to conduct a virtual screen of commercial compound databases that selected a small library of ten compounds. These molecules were then screened in mouse neuroblastoma cell line chronically infected with prions (ScN2a) after excluding neurotoxicity. 1 has been identified as the therapeutic hit on the basis of the following evidence: chronic treatments of ScN2a cells using 1 eliminate PrPSc loaded in both Western blotting analysis and Real-Time Quaking-Induced Conversion (RT-QuIC) assay. We also proposed the mechanism of action of 1 by which it has the ability to bind PrPC and consequentially blocks prion conversion. Herein we describe the results of these efforts.

Design, Synthesis, and Biological Evaluation of Scutellarein Derivatives Based on Scutellarin Metabolic Mechanism in Vivo

Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. Their thrombin inhibition activities were tested through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and the ability to protect PC12 cells against H2O2-induced cytotoxicity, and their solubilities were evaluated by ultraviolet (UV) spectrophotometer. The results showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment. Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. The results of the biological evaluation showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment.

HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.